This paper gives an overview of economic assessments of the benefits of the control of 1-Methyl-2-pyrrolidone (NMP), an organic solvent, used in a number of sectors. Health risks associated with the manufacture of NMP include the risk of stillbirth and developmental retardation to pregnant workers, as well as a variety of chronic and acute effects, including respiratory effects.
Economic valuation in 1-Methyl-2‑pyrrolidone (NMP) regulation
Working paper
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
Working paper
A large‑scale multi‑country stated preference approach
20 May 202669 Pages -
Working paper
The role of innovation across the supply chain
27 April 202675 Pages -
Working paper
A large‑scale multi‑country stated preference approach
7 April 202675 Pages -
Working paper
A large‑scale multi‑country stated preference approach
7 April 202671 Pages -
Working paper
A large‑scale multi‑country stated preference approach
7 April 202673 Pages -
27 January 202644 Pages
-
Working paper
Lessons from international case studies and toolkit for policymakers
9 January 202677 Pages -
Working paper
A literature review
22 December 202566 Pages
Related publications
-
Working paper
A large‑scale multi‑country stated preference approach
20 May 202669 Pages -
Working paper
A large‑scale multi‑country stated preference approach
7 April 202675 Pages -
Working paper
A large‑scale multi‑country stated preference approach
7 April 202671 Pages -
Working paper
A large‑scale multi‑country stated preference approach
7 April 202673 Pages -
14 November 2025146 Pages
-
Report
Report on Commercial Availability and Current Uses
20 June 202587 Pages -
16 December 202419 Pages